Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | trypanothione reductase, putative | 0.0042 | 0.0216 | 0.5 |
Mycobacterium leprae | PROBABLE ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT 1 CLPP1 (ENDOPEPTIDASE CLP) | 0.0046 | 0.0259 | 0.2616 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0096 | 0.0861 | 0.8342 |
Leishmania major | trypanothione reductase | 0.0042 | 0.0216 | 0.5 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0107 | 0.0989 | 1 |
Mycobacterium ulcerans | ATP-dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 0.5 |
Plasmodium vivax | glutathione reductase, putative | 0.0042 | 0.0216 | 0.2061 |
Toxoplasma gondii | kinesin motor domain-containing protein | 0.0112 | 0.105 | 1 |
Plasmodium falciparum | ATP-dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 0.5193 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0096 | 0.0861 | 0.8342 |
Echinococcus granulosus | ATP dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 0.0336 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0042 | 0.0216 | 0.2061 |
Chlamydia trachomatis | ATP-dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 0.5 |
Plasmodium falciparum | glutathione reductase | 0.0042 | 0.0216 | 0.2061 |
Mycobacterium tuberculosis | Probable ATP-dependent CLP protease proteolytic subunit 2 ClpP2 (endopeptidase CLP 2) | 0.0046 | 0.0259 | 0.0547 |
Plasmodium falciparum | kinesin-5 | 0.0112 | 0.105 | 1 |
Mycobacterium leprae | PROBABLE ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT 2 CLPP2 (ENDOPEPTIDASE CLP 2) | 0.007 | 0.0545 | 0.5514 |
Mycobacterium ulcerans | ATP-dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 0.5 |
Echinococcus multilocularis | ATP dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 0.0336 |
Echinococcus granulosus | peptidase Clp S14 family | 0.0046 | 0.0259 | 0.0043 |
Echinococcus multilocularis | kinesin family 1 | 0.0862 | 1 | 1 |
Plasmodium vivax | kinesin-5 | 0.0112 | 0.105 | 1 |
Brugia malayi | Kinesin motor domain containing protein | 0.0112 | 0.105 | 1 |
Entamoeba histolytica | kinesin, putative | 0.0112 | 0.105 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.075 | 0.8664 | 1 |
Echinococcus multilocularis | peptidase Clp (S14 family) | 0.0046 | 0.0259 | 0.0043 |
Toxoplasma gondii | ATP-dependent Clp endopeptidase, proteolytic subunit ClpP domain-containing protein | 0.007 | 0.0545 | 0.5193 |
Mycobacterium leprae | PROBABLE NADH DEHYDROGENASE NDH | 0.0096 | 0.0861 | 0.8705 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0107 | 0.0989 | 1 |
Giardia lamblia | Kinesin-5 | 0.0112 | 0.105 | 0.5 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0096 | 0.0861 | 0.8342 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0107 | 0.0989 | 1 |
Chlamydia trachomatis | ATP-dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.007 | 0.0545 | 0.3945 |
Schistosoma mansoni | kinesin eg-5 | 0.0112 | 0.105 | 0.0622 |
Wolbachia endosymbiont of Brugia malayi | ATP-dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 0.5 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0096 | 0.0861 | 0.8342 |
Treponema pallidum | ATP-dependent Clp protease proteolytic subunit | 0.007 | 0.0545 | 1 |
Trypanosoma brucei | trypanothione reductase | 0.0042 | 0.0216 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0107 | 0.0989 | 1 |
Toxoplasma gondii | ATP-dependent Clp endopeptidase, proteolytic subunit ClpP domain-containing protein | 0.007 | 0.0545 | 0.5193 |
Plasmodium falciparum | thioredoxin reductase | 0.0042 | 0.0216 | 0.2061 |
Plasmodium vivax | ATP-dependent Clp protease proteolytic subunit, putative | 0.007 | 0.0545 | 0.5193 |
Mycobacterium tuberculosis | Probable ATP-dependent CLP protease proteolytic subunit 1 ClpP1 (endopeptidase CLP) | 0.0046 | 0.0259 | 0.0547 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0096 | 0.0861 | 0.8342 |
Mycobacterium tuberculosis | Probable reductase | 0.0096 | 0.0861 | 0.8342 |
Brugia malayi | Probable ClpP-like protease | 0.007 | 0.0545 | 0.3945 |
Loa Loa (eye worm) | kinesin-like protein KLP2 | 0.0112 | 0.105 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0042 | 0.0216 | 0.2061 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 100 uM | Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs | ChEMBL. | 17960925 |
IC50 (functional) | > 100 uM | Antimalarial activity against Plasmodium falciparum D10 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs | ChEMBL. | 17960925 |
IC50 (functional) | > 100 uM | Antimalarial activity against drug-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs | ChEMBL. | 17960925 |
IC50 (functional) | > 100 uM | Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs | ChEMBL. | 17960925 |
IC50 (functional) | > 100 uM | Antimalarial activity against Plasmodium falciparum D10 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs | ChEMBL. | 17960925 |
IC50 (functional) | > 100 uM | Antimalarial activity against drug-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs | ChEMBL. | 17960925 |
Ki (binding) | 0 | Inhibition of porcine kidney M17 LAP | ChEMBL. | 17960925 |
Ki (binding) | = 524.8 nM | Inhibition of Plasmodium falciparum recombinant M17 LAP | ChEMBL. | 17960925 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.